Re: VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials: Editorial comment

Samir S. Taneja

doi:10.1016/j.juro.2012.08.165

Re: VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials: Editorial comment

Samir S. Taneja

Biomedical Engineering

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	2145-2146
Number of pages	2
Journal	Journal of Urology
Volume	188
Issue number	6
DOIs	https://doi.org/10.1016/j.juro.2012.08.165
State	Published - Dec 2012

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2012.08.165

Cite this

@article{e639a25483574bcf8593f911f387974c,

title = "Re: VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials: Editorial comment",

author = "Taneja, {Samir S.}",

year = "2012",

month = dec,

doi = "10.1016/j.juro.2012.08.165",

language = "English (US)",

volume = "188",

pages = "2145--2146",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Re

T2 - VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials: Editorial comment

AU - Taneja, Samir S.

PY - 2012/12

Y1 - 2012/12

UR - http://www.scopus.com/inward/record.url?scp=84869009380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869009380&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.08.165

DO - 10.1016/j.juro.2012.08.165

M3 - Comment/debate

C2 - 23141216

AN - SCOPUS:84869009380

SN - 0022-5347

VL - 188

SP - 2145

EP - 2146

JO - Journal of Urology

JF - Journal of Urology

IS - 6

ER -

Re: VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the AViTA and AVOREN randomised trials: Editorial comment

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this